145 related articles for article (PubMed ID: 25834026)
1. A licence to cure.
Aronson JK; Ferner RE
BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
[No Abstract] [Full Text] [Related]
2. Why have UK doctors been deterred from prescribing Avastin?
Cohen D
BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024
[No Abstract] [Full Text] [Related]
3. Why using Avastin for eye disease is so difficult.
Torjesen I
BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
[No Abstract] [Full Text] [Related]
4. Cost comparison of ranibizumab and bevacizumab.
Jackson TL; Kirkpatrick L
BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536
[No Abstract] [Full Text] [Related]
5. CCGs face legal threat for offering off-label drug for wet AMD.
Cohen D
BMJ; 2017 Oct; 359():j5021. PubMed ID: 29089307
[No Abstract] [Full Text] [Related]
6. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
Torjesen I
BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
[No Abstract] [Full Text] [Related]
7. Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
Hawkes N
BMJ; 2012 Jul; 345():e5161. PubMed ID: 22846417
[No Abstract] [Full Text] [Related]
8. Avastin and Lucentis: a guide through the legal maze.
Lock D
BMJ; 2015 Apr; 350():h1377. PubMed ID: 25834023
[No Abstract] [Full Text] [Related]
9. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
Torjesen I
BMJ; 2012 Apr; 344():e2959. PubMed ID: 22532011
[No Abstract] [Full Text] [Related]
10. Legal. PCTs taken to court over use of cheaper drug.
Calkin S
Health Serv J; 2012 Apr; 122(6303):10-1. PubMed ID: 22741353
[No Abstract] [Full Text] [Related]
11. [Age-related visual loss].
Neubauer AS; Kernt M
MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
[No Abstract] [Full Text] [Related]
12. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
Formoso G; Marata AM; Magrini N; Bero L
Cochrane Database Syst Rev; 2014 Sep; 2014(9):ED000090. PubMed ID: 25228121
[No Abstract] [Full Text] [Related]
13. Attacks on publicly funded trials: what happens when industry does not want to know the answer.
Cohen D
BMJ; 2015 Apr; 350():h1701. PubMed ID: 25834025
[No Abstract] [Full Text] [Related]
14. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
Hawkes N
BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
[No Abstract] [Full Text] [Related]
15. Bevacizumab versus ranibizumab: why are we not playing the joker?
Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
[No Abstract] [Full Text] [Related]
16. Prescribing bevacizumab off-label contravenes GMC advice.
Kyle G
BMJ; 2011 Nov; 343():d7131. PubMed ID: 22077076
[No Abstract] [Full Text] [Related]
17. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
Rhodes C; Harris J; Sulston J; Spanswick C
J Med Ethics; 2012 Mar; 38(3):187-9. PubMed ID: 21947806
[TBL] [Abstract][Full Text] [Related]
18. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
Silver J
JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
[No Abstract] [Full Text] [Related]
19. [Avastin-Lucentis: off-label and surroundings].
Messori A
Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536
[TBL] [Abstract][Full Text] [Related]
20. Licence to save: a UK survey of anti-VEGF use for the eye in 2015.
Shalaby AK; Lewis K; Bush K; Meredith PR; Di Simplicio S; Lockwood AJ
Eye (Lond); 2016 Nov; 30(11):1404-1406. PubMed ID: 27518544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
